Lederle

Executive Summary

Countersues Mylan May 28 in Clarksburg, W.V. federal court in response to Mylan's November 1990 suit claiming that Lederle failed to adequately support Maxzide (triamterene/hydrochlorothiazide), resulting in "underpayment" to Mylan ("The Pink Sheet" Dec. 10, T&G-2). Lederle, which is seeking $ 607 mil. in compensatory damages and $ 75 mil. in punitive damages, denies all of Mylan's claims and makes counterclaims for: fraudulent inducement, alleging that Mylan misrepresented its patented process to preclude competition; breach of contract, by failing to satisfy the challenge of bioavailability; and defamation, by allegedly making false statements that parent American Cyanamid was not placing Maxzide orders with Mylan.